بدائل البحث:
non decrease » point decrease (توسيع البحث), note decreased (توسيع البحث), fold decrease (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), gy decreased (توسيع البحث), b1 decreased (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
non decrease » point decrease (توسيع البحث), note decreased (توسيع البحث), fold decrease (توسيع البحث)
nn decrease » _ decrease (توسيع البحث), gy decreased (توسيع البحث), b1 decreased (توسيع البحث)
a decrease » _ decrease (توسيع البحث), _ decreased (توسيع البحث), _ decreases (توسيع البحث)
-
61
-
62
Comparison of non-pregnant (adult female) women RIs of our study with those found in the literature.
منشور في 2022الموضوعات: -
63
mTORC1 hyperactivation led to a decreased autophagic activity in the podocytes.
منشور في 2020"…(<b>B</b>) <i>FIP200</i> and <i>ATG101</i> mRNA expressions were decreased in the primary cultured podocytes from <i>Tsc2</i><sup>Δ<i>podocyte</i></sup>. …"
-
64
-
65
Proportion of stroke subtypes according to age among young adults versus non-young adults.
منشور في 2022الموضوعات: -
66
-
67
-
68
Prevalence of vascular risk factors according to age among young adults versus non-young adults.
منشور في 2022الموضوعات: -
69
-
70
-
71
Data_Sheet_1_Effectiveness of non-pharmaceutical interventions in nine fields of activity to decrease SARS-CoV-2 transmission (Spain, September 2020–May 2021).PDF
منشور في 2023"…Background<p>We estimated the association between the level of restriction in nine different fields of activity and SARS-CoV-2 transmissibility in Spain, from 15 September 2020 to 9 May 2021.</p>Methods<p>A stringency index (0–1) was created for each Spanish province (n = 50) daily. …"
-
72
-
73
-
74
-
75
-
76
-
77
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
منشور في 2025"…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …"
-
78
-
79
-
80